Drug intelligence / Profile preview

NAL1282

Development stage: Preclinical
Lead developer: Nal Pharmaceuticals
Modality: Small Molecules
Administration: Transdermal

Overview

NAL1282 is a transdermal patch formulation containing 5% lidocaine, developed by NAL Pharmaceutical Group for the management of pain. As a local anesthetic, lidocaine works by blocking voltage-gated sodium channels on the neuronal membrane, which prevents the initiation and conduction of nerve impulses, thereby providing analgesic effects. The NAL1282 patch is designed for a 12-hour application period and is currently in the preclinical stage of development.

Other names: Lidocaine 5% 12-Hour Patchlidocaine

Targets

SCN5A (Sodium channel protein type 5 subunit alpha)

Beyond the preview

Go deeper on NAL1282.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NAL1282.

Explore the full profile